Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

HeartSciences (HSCS) Net Income towards Common Stockholders (2021 - 2026)

HeartSciences' Net Income towards Common Stockholders history spans 6 years, with the latest figure at -$2.0 million for Q1 2026.

  • For Q1 2026, Net Income towards Common Stockholders rose 21.97% year-over-year to -$2.0 million; the TTM value through Jan 2026 reached -$8.5 million, up 1.73%, while the annual FY2025 figure was -$8.9 million, 32.93% down from the prior year.
  • Net Income towards Common Stockholders reached -$2.0 million in Q1 2026 per HSCS's latest filing, up from -$2.4 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of -$1.2 million in Q1 2022 to a low of -$2.6 million in Q1 2025.
  • Average Net Income towards Common Stockholders over 5 years is -$1.9 million, with a median of -$1.9 million recorded in 2024.
  • Peak YoY movement for Net Income towards Common Stockholders: plummeted 109.25% in 2022, then rose 21.97% in 2026.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$1.8 million in 2022, then grew by 3.28% to -$1.7 million in 2023, then fell by 20.26% to -$2.1 million in 2024, then decreased by 11.9% to -$2.4 million in 2025, then increased by 15.41% to -$2.0 million in 2026.
  • Per Business Quant, the three most recent readings for HSCS's Net Income towards Common Stockholders are -$2.0 million (Q1 2026), -$2.4 million (Q4 2025), and -$2.1 million (Q3 2025).